ArticleFrontiers in oncology2024

Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial.

Tal Sigawi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.